

OCT. 10. 2007 3:54PM +1-212-319-5101 customer 01933

NO. 1664 P. 2

RECEIVED
CENTRAL FAX CENTER

OCT 10 2007

Appl. No. 10/576,402

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1 to 3. (canceled)

Claim 4. (currently amended) A method for treating a keratoconjunctival disorder comprising administering to a patient in need thereof a therapeutically effective amount of a compound selected from the group consisting of

- (i) 5-[4-[[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy] phenylmethyl]thiazolidine-2,4-dione [[,]] or a pharmaceutically acceptable salt thereof, and
- (ii) N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine or a pharmaceutically acceptable salt thereof.

Claim 5. (currently amended) The therapeutic method according to Claim 4, wherein the keratoconjunctival disorder is dry eyes, corneal ulcer, keratitis, conjunctivitis, superficial

Appl. No. 10/576,402

punctate keratopathy, corneal epithelial defects, conjunctive epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis [[and]] or filamentary keratitis.

Claim 6. (currently amended) The ~~therapeutic~~ method according to Claim 4, wherein the administration is instillation of an eye drop or administration of an ophthalmic ointment.

Claims 7 to 9. (canceled)

Claim 10. (new) The method according to claim 4, wherein the compound is 5-[4-[[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy] phenylmethyl]thiazolidine-2,4-dione or a pharmaceutically acceptable salt thereof.

Claim 11. (new) The method according to claim 4, wherein the compound is N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine or a pharmaceutically acceptable salt thereof.